Skip to main content
Terug
SHJBF logo

Shanghai Junshi Biosciences Co., Ltd.

Datakwaliteit: 100%
Overbought
SHJBF
OTC Healthcare Biotechnology
€ 3,00
€ 0,00 (0,00%)
Marktkapitalisatie: 4,34B
Dagbereik
€ 3,00 € 3,00
52-Weeksbereik
€ 1,97 € 4,23
Volume
1.000
50D / 200D Gem.
€ 3,00 / € 2,99
Vorige Slotkoers
€ 3,00

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E -5,1 0,3
P/B 0,7 2,9
ROE % -14,3 3,7
Net Margin % -35,0 3,8
Rev Growth 5Y % -11,8 10,0
D/E 0,7 0,2

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2028 -€ 0,12
-€ 0,13 – -€ 0,12
5,2 B 1
FY2027 -€ 0,22
-€ 0,23 – -€ 0,21
4,1 B 1
FY2026 -€ 0,52
-€ 0,54 – -€ 0,50
3,3 B 1

Belangrijkste Punten

Revenue declined -11,82% annually over 5 years
Negative free cash flow of -1,21B
PEG of 0,72 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 36,75%
Capital intensive — 30,75% of revenue goes to capex

Groei

Revenue Growth (5Y)
-11,82%
Revenue (1Y)24,93%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-14,30%
ROIC-6,70%
Net Margin-35,00%
Op. Margin-37,37%

Veiligheid

Debt / Equity
0,69
Current Ratio1,60
Interest Coverage-12,37

Waardering

P/E Ratio
-5,09
P/B Ratio0,72
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 24,93% Revenue Growth (3Y) 27,27%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -11,82% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 2,43B Net Income (TTM) -851,83M
ROE -14,30% ROA -6,88%
Gross Margin 72,34% Operating Margin -37,37%
Net Margin -35,00% Free Cash Flow (TTM) -1,21B
ROIC -6,70% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,69 Current Ratio 1,60
Interest Coverage -12,37 Dividend Yield 0,00%
Valuation
P/E Ratio -5,09 P/B Ratio 0,72
P/S Ratio 1,78 PEG Ratio 0,72
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 4,34B Enterprise Value 5,86B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 2,43B 1,95B 1,50B 1,45B 4,02B
Net Income -851,83M -1,28B -2,28B -2,39B -718,56M
EPS (Diluted) -0,84 -1,30 -2,32 -2,60 -0,81
Gross Profit 1,76B 1,45B 835,26M 927,21M 2,77B
Operating Income -909,47M -1,30B -2,45B -2,75B -592,71M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 12,39B 10,80B 11,36B 12,56B 11,05B
Total Liabilities 6,16B 4,85B 4,02B 2,78B 2,72B
Shareholders' Equity 6,03B 5,88B 7,17B 9,48B 7,96B
Total Debt 4,14B 2,93B 1,79B 1,32B 628,20M
Cash & Equivalents 2,62B 2,49B 3,78B 6,00B 3,50B
Current Assets 4,46B 4,28B 5,55B 7,22B 5,83B
Current Liabilities 2,78B 2,53B 2,48B 1,77B 2,02B